🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Shaping neonatal immunization by tuning delivery of synergistic adjuvants via nanocarriers biorxiv.org/cgi/content/sh… #bioRxiv

Shaping neonatal immunization by tuning delivery of synergistic adjuvants via nanocarriers dlvr.it/SRgmQK

New: Shaping neonatal immunization by tuning delivery of synergistic adjuvants via nanocarriers dx.doi.org/10.1101/2022.0… read/write/request review outbreaksci.prereview.org #influenza

What’s the evidence for SARS-CoV-2 booster shots? In this study from our group, we investigated longitudinal immunization of mRNA BNT162b2 across the lifespan - showing mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant rdcu.be/cTaql

Recent article in ACS Publications led by Precision Vaccines Program researchers, Drs. Dr. David J. Dowling, Ph.D. & Soumik Barman indicates an adjuvanted nanocarrier-based vaccine that activates early life type 1 immune responses. ow.ly/ZCjj50KIEG5

Congrats to Precision Vaccines Program member Dr. Soumik Barman on his promotion to Senior Staff Scientist within the Dowling Lab!

New article in Scientific Reports led by Precision Vaccines Program researchers Drs Dr. David J. Dowling, Ph.D., Soumik Barman & Dr. Ofer Levy, MD PhD indicates a novel small molecule imidazoquinoline TLR7/8 #adjuvant overcomes neonatal hyporesponsiveness to a licensed acellular #pertussis #vaccine. go.nature.com/3D60z52

New paper from our Precision Vaccines Program team, out now in Journal of Allergy and Clinical Immunology, showing how Type 2 diabetes and obesity, in parallel with increasing age, impair COVID-19 mRNA vaccine responses - sciencedirect.com/science/articl…

Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro - researchsquare.com/article/rs-337…

Precision Vaccines Program team had a great time watching the solar eclipse this afternoon in Boston! Dr. Ofer Levy, MD PhD Byron Brook Soumik Barman #Eclipse2024 😎

An in vitro mass cytometry study focusing on age and adjuvant-specific activation of human blood mononuclear cells reveals NK cells as the key source of TLR7/8 agonist induced innate IFNγ responses.Soumik Barman Dr. David J. Dowling, Ph.D. Dr. Ofer Levy, MD PhD Precision Vaccines Program nature.com/articles/s4200…

New article in Nature Portfolio’s Communications Biology led by Precision Vaccines Program researchers Simone Schüller, Soumik Barman, Dr. Ofer Levy, MD PhD & Dr. David J. Dowling, Ph.D. characterizes adjuvant-specific innate immune responses across the human lifespan. Schüller and Barman et al. 2024: nature.com/articles/s4200…

New article in Communications Biology led by Precision Vaccines Program researchers Drs Soumik Barman, Dr. Ofer Levy, MD PhD & Dr. David J. Dowling, Ph.D. characterizes adjuvant specific innate immune responses across life span using cutting-edge CyTOF technology and computational approaches. #CyTOF nature.com/articles/s4200…

Great news! A Precision Vaccines Program team led by Drs Dr. Ofer Levy, MD PhD & Dr. David J. Dowling, Ph.D. identified PVP-037, a novel small molecule #adjuvant that may enhance immunogenicity of vaccines for various diseases, including allergy, oncology, and opioid #overdose. 🎆 #biotech science.org/doi/10.1126/sc…

“From hit to vial” – We did something special with the discovery of our exciting new TLR7/8 agonist adjuvant family - essentially condensing a full vaccine development pipeline lifecycle into a single manuscript – Today, we are happy to introduce PVP-037. Precision Vaccines Program

Excited to share our publication in Science Advances for #PVP-037 titled “From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation” science.org/doi/10.1126/sc…

Very proud of our Precision Vaccines Program team including Byron Brook Brook, Soumik Barman, Joann Arce, PhD and Dr. David J. Dowling, Ph.D. for their excellent work on modeling age-specific resposes to mRNA vaccines in vitro just published in iScience journal cell.com/iscience/fullt…